Reshma Kewalramani - Jun 12, 2024 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Director
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Jun 12, 2024
Transactions value $
$0
Form type
4
Date filed
6/14/2024, 04:24 PM
Previous filing
May 29, 2024
Next filing
Jul 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +105K +130.37% 186K Jun 12, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -105K -100% 0 Jun 12, 2024 Class A Common Stock 105K $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Reshma Kewalramani is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.